Online Purchasing Account You are logged on as Guest. LoginRegister a New AccountShopping cart (Empty)
United States 

IL-1F9 (human), (recombinant)

ALX-522-130-C050 50 µg 332.00 USD
Bulk Request

Product Specification

Alternative Name:Interleukin-1ε, IL-1ε, Interleukin-1 family member 9, IL-36γ, Interleukin-36γ
MW:~18kDa (SDS-PAGE)
Source:Produced in E. coli (aa 1-169).
UniProt ID:Q9NZH8
Concentration:1mg/ml after reconstitution.
Formulation:Lyophilized. Contains PBS.
Purity:≥95% (SDS-PAGE)
Endotoxin Content:<0.1EU/µg purified protein (LAL test; Associates of Cape Cod).
Reconstitution:Reconstitute with 50µl sterile water. Further dilutions should be made with medium containing 5% fetal calf serum.
Long Term Storage:-20°C
Use/Stability:Stable for at least 6 months after receipt when stored at -20°C.
Handling:Avoid freeze/thaw cycles. After reconstitution, prepare aliquots and store at -20°C.
Scientific Background:IL-1F5, F6, F8 and F9 are members of the family of IL-1 (IL-1α/β, IL-18, IL-33). IL-1F6, IL-1F8 and IL-1F9 activate the NF-κB and MAPK pathways through the IL-Rrp2 and IL-1RAcP receptor complex leading to the production of IL-6 and IL-8. Agonistic activation of the IL-1F6, F8 and F9 is counterbalanced by the inhibitory activity of IL-1F5. These interleukins are mainly expressed in skin keratinocytes and internal epithelial tissues exposed to pathogenic bacteria suggesting a role in immune signalling and inflammation. IL-F5, F6 and F9 as well as the receptor IL-1Rrp2 are increased in psoriasis.

General Literature References

Interleukin (IL)-1F6, IL-1F8, and IL-1F9 signal through IL-1Rrp2 and IL-1RAcP to activate the pathway leading to NF-kappaB and MAPKs: J.E. Towne, et al.; J. Biol. Chem. 279, 13677 (2004), Abstract; Full Text

Product Toolbox


Print as PDF
Certificate of Analysis


By target:
By biological activity:
IL-1 Recombinant protein
By catalog section:


Technical Service
Bulk Quantity Quote
Customer Service

Recommend this page

Keep in touch

©2015 Enzo Life Sciences, Inc.,